Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting

Anthony, 2014, Regulation of hematopoietic stem cells by bone marrow stromal cells, Trends Immunol., 35, 32, 10.1016/j.it.2013.10.002

Balakrishnan, 2017, Analysis of ROR1 protein expression in human cancer and normal tissues, Clin. Cancer Res., 23, 3061, 10.1158/1078-0432.CCR-16-2083

Berger, 2015, Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells, Cancer Immunol. Res., 3, 206, 10.1158/2326-6066.CIR-14-0163

Bourquin, C., Castoldi, R., Endres, S., Klein, C., Kobold, S., Niederfellner, G., Sustmann, C., 2015. Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine. US patent application publication 20150010567A1, filed January 24, 2013, and published January 8, 2015.

Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751

Castagnaro, 2013, Nkx2-5(+)islet1(+) mesenchymal precursors generate distinct spleen stromal cell subsets and participate in restoring stromal network integrity, Immunity, 38, 782, 10.1016/j.immuni.2012.12.005

Chien, 2016, Expression of ROR1 has prognostic significance in triple negative breast cancer, Virchows Arch., 468, 589, 10.1007/s00428-016-1911-3

Choi, 2018, Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia, Cell Stem Cell, 22, 951, 10.1016/j.stem.2018.05.018

Choi, 2015, Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1, Clin. Lymphoma Myeloma Leuk., 15 Suppl, S167, 10.1016/j.clml.2015.02.010

Dimarino, 2013, Mesenchymal stem cells in tissue repair, Front. Immunol., 4, 201, 10.3389/fimmu.2013.00201

Grada, 2013, TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy, Mol. Ther. Nucleic Acids, 2, e105, 10.1038/mtna.2013.32

Greaves, 2012

Hay, 2017, Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy, Blood, 130, 2295, 10.1182/blood-2017-06-793141

Ho, 2012, Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis, Proc. Natl. Acad. Sci. U S A, 109, 4044, 10.1073/pnas.1200421109

Hudecek, 2013, Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells, Clin. Cancer Res., 19, 3153, 10.1158/1078-0432.CCR-13-0330

Hudecek, 2010, The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor, Blood, 116, 4532, 10.1182/blood-2010-05-283309

Hudecek, 2015, The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity, Cancer Immunol. Res., 3, 125, 10.1158/2326-6066.CIR-14-0127

Inra, 2015, A perisinusoidal niche for extramedullary haematopoiesis in the spleen, Nature, 527, 466, 10.1038/nature15530

Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat. Biotechnol., 31, 71, 10.1038/nbt.2459

Kochenderfer, 2013, Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors, Nat. Rev. Clin. Oncol., 10, 267, 10.1038/nrclinonc.2013.46

Lamers, 2013, Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity, Mol. Ther., 21, 904, 10.1038/mt.2013.17

Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J. Clin. Oncol., 24, e20, 10.1200/JCO.2006.05.9964

Li, 2017, Increasing the safety and efficacy of chimeric antigen receptor T cell therapy, Protein Cell, 8, 573, 10.1007/s13238-017-0411-9

Liu, 2009, Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells, J. Cell Biol., 185, 67, 10.1083/jcb.200810137

Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol. Ther., 18, 843, 10.1038/mt.2010.24

O'Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci. Transl. Med., 9

Potratz, 2016, Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease, Mol. Oncol., 10, 677, 10.1016/j.molonc.2015.12.009

Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967

Roybal, 2016, Precision tumor recognition by T cells with combinatorial antigen-sensing circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011

Seita, 2012, Gene Expression Commons: an open platform for absolute gene expression profiling, PLoS One, 7, e40321, 10.1371/journal.pone.0040321

Soneoka, 1995, A transient three-plasmid expression system for the production of high titer retroviral vectors, Nucleic Acids Res., 23, 628, 10.1093/nar/23.4.628

Srivastava, 2018, Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy, J. Immunol., 200, 459, 10.4049/jimmunol.1701155

Srivastava, 2015, Engineering CAR-T cells: design concepts, Trends Immunol., 36, 494, 10.1016/j.it.2015.06.004

Tan, 2017, Stromal cell subsets directing neonatal spleen regeneration, Sci. Rep., 7, 40401, 10.1038/srep40401

Uhlén, 2015, Proteomics. Tissue-based map of the human proteome, Science, 347, 1260419, 10.1126/science.1260419

Wang, 2011, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 118, 1255, 10.1182/blood-2011-02-337360

Wilkie, 2012, Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling, J. Clin. Immunol., 32, 1059, 10.1007/s10875-012-9689-9

Yang, 2011, Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies, PLoS One, 6, e21018, 10.1371/journal.pone.0021018

Zheng, 2016, ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma, Sci. Rep., 6, 36447, 10.1038/srep36447